390 related articles for article (PubMed ID: 33801599)
1. Gene Transactivation and Transrepression in MYC-Driven Cancers.
Scafuro M; Capasso L; Carafa V; Altucci L; Nebbioso A
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801599
[No Abstract] [Full Text] [Related]
2. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.
Chandramohan V; Mineva ND; Burke B; Jeay S; Wu M; Shen J; Yang W; Hann SR; Sonenshein GE
J Cell Biochem; 2008 Aug; 104(6):2091-106. PubMed ID: 18393360
[TBL] [Abstract][Full Text] [Related]
3. Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest.
Acosta JC; Ferrándiz N; Bretones G; Torrano V; Blanco R; Richard C; O'Connell B; Sedivy J; Delgado MD; León J
Mol Cell Biol; 2008 Dec; 28(24):7286-95. PubMed ID: 18838534
[TBL] [Abstract][Full Text] [Related]
4. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
[TBL] [Abstract][Full Text] [Related]
5. DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.
Xu J; Testa JR
J Biol Chem; 2009 Jul; 284(31):20593-601. PubMed ID: 19497851
[TBL] [Abstract][Full Text] [Related]
6. The proto-oncogene c-myc in hematopoietic development and leukemogenesis.
Hoffman B; Amanullah A; Shafarenko M; Liebermann DA
Oncogene; 2002 May; 21(21):3414-21. PubMed ID: 12032779
[TBL] [Abstract][Full Text] [Related]
7. Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells.
La T; Chen S; Guo T; Zhao XH; Teng L; Li D; Carnell M; Zhang YY; Feng YC; Cole N; Brown AC; Zhang D; Dong Q; Wang JY; Cao H; Liu T; Thorne RF; Shao FM; Zhang XD; Jin L
Theranostics; 2021; 11(19):9605-9622. PubMed ID: 34646389
[No Abstract] [Full Text] [Related]
8. Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer.
Yang Z; Shah K; Busby T; Giles K; Khodadadi-Jamayran A; Li W; Jiang H
J Clin Invest; 2018 Aug; 128(8):3605-3618. PubMed ID: 29870403
[TBL] [Abstract][Full Text] [Related]
9. MYC activation is a hallmark of cancer initiation and maintenance.
Gabay M; Li Y; Felsher DW
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
[TBL] [Abstract][Full Text] [Related]
10. ZFP281 Recruits MYC to Active Promoters in Regulating Transcriptional Initiation and Elongation.
Luo Z; Liu X; Xie H; Wang Y; Lin C
Mol Cell Biol; 2019 Dec; 39(24):. PubMed ID: 31570506
[TBL] [Abstract][Full Text] [Related]
11. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
12. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.
Stefan E; Bister K
Curr Top Microbiol Immunol; 2017; 407():117-151. PubMed ID: 28466200
[TBL] [Abstract][Full Text] [Related]
13. circCTIC1 promotes the self-renewal of colon TICs through BPTF-dependent c-Myc expression.
Zhan W; Liao X; Wang Y; Li L; Li J; Chen Z; Tian T; He J
Carcinogenesis; 2019 Jun; 40(4):560-568. PubMed ID: 30403769
[TBL] [Abstract][Full Text] [Related]
14. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
15. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
16. The ARF tumor suppressor: keeping Myc on a leash.
Gregory MA; Qi Y; Hann SR
Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
[TBL] [Abstract][Full Text] [Related]
17. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
Sipos F; Firneisz G; Műzes G
World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
[TBL] [Abstract][Full Text] [Related]
19. Chromatin remodeler HELLS maintains glioma stem cells through E2F3 and MYC.
Zhang G; Dong Z; Prager BC; Kim LJ; Wu Q; Gimple RC; Wang X; Bao S; Hamerlik P; Rich JN
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30779712
[TBL] [Abstract][Full Text] [Related]
20. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
